ETR:GXI - Gerresheimer Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started €66.05 -0.25 (-0.38 %) (As of 05/26/2019 01:35 PM ET)Previous Close€66.05Today's Range€65.70 - €66.9052-Week Range€51.10 - €80.25Volume78,594 shsAverage Volume140,925 shsMarket Capitalization$2.07 billionP/E Ratio11.57Dividend Yield1.72%BetaN/A ProfileAnalyst RatingsChartHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices. It also provides containers for the delivery of tablets and powders, liquid dosages, ophthalmic and rhinological applications, parenteral packaging applications, oral prescription medications, and cosmetics. The Primary Packaging Glass division offers glass primary packaging for medicines and cosmetics, such as ampoules, cartridges, vials, syrup and dropper bottles, tablet jars, and wide-neck jars, as well as injection, infusion, and transfusion bottles; flacons and pots for fragrances, deodorants, and care and decorative cosmetics; and bottles and jars for spirits and food. The Advanced Technologies division develops drug delivery products and platforms, such as micro pumps, which are used to self-administer medication for diabetes or Parkinson's for pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in Düsseldorf, Germany. Receive GXI News and Ratings via Email Sign-up to receive the latest news and ratings for GXI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange ETR Industry Medical Instruments & Supplies Sub-IndustryN/A SectorMedical Current SymbolETR:GXI Previous Symbol CUSIPN/A CIKN/A Webhttp://www.gerresheimer.com/ Phone+49-211-618100Debt Debt-to-Equity Ratio68.19 Current Ratio0.78 Quick Ratio0.51Price-To-Earnings Trailing P/E Ratio11.57 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.39 billion Price / Sales1.50 Cash Flow€3.10 per share Price / Cash Flow21.30 Book Value€31.07 per share Price / Book2.13Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees9,867 Outstanding Shares31,400,000Market Cap$2.07 billion Next Earnings Date7/11/2019 (Estimated) OptionableNot Optionable Gerresheimer (ETR:GXI) Frequently Asked Questions What is Gerresheimer's stock symbol? Gerresheimer trades on the ETR under the ticker symbol "GXI." When is Gerresheimer's next earnings date? Gerresheimer is scheduled to release their next quarterly earnings announcement on Thursday, July 11th 2019. View Earnings Estimates for Gerresheimer. What price target have analysts set for GXI? 12 analysts have issued 12-month price targets for Gerresheimer's shares. Their forecasts range from €50.00 to €84.00. On average, they anticipate Gerresheimer's stock price to reach €69.17 in the next year. This suggests a possible upside of 4.7% from the stock's current price. View Analyst Price Targets for Gerresheimer. What is the consensus analysts' recommendation for Gerresheimer? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gerresheimer in the last year. There are currently 3 sell ratings, 6 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Gerresheimer. Has Gerresheimer been receiving favorable news coverage? Media stories about GXI stock have been trending negative on Sunday, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Gerresheimer earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an effect on the company's share price in the near term. Who are some of Gerresheimer's key competitors? Some companies that are related to Gerresheimer include Ansell (ANN), Enerplus (ERF), RESMED/IDR UNRESTR (RMD), Nanosonics (NAN), Advanced Medical Solutions Group (AMS), Clover (CLV), CRH Medical (CRH), TransEnterix (TRXC), Bovie Medical (BVX), Bovie Medical (BVX), CRH Medical (CRHM), CRH Medical (CRHM), Tristel (TSTL), SDI (SDI) and InfuSystem (INFU). What other stocks do shareholders of Gerresheimer own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gerresheimer investors own include Inogen (INGN), Haynes International (HAYN), Cree (CREE), Capitala Finance (CPTA), Clearone (CLRO), Boston Private Financial (BPFH), Biocept (BIOC), Brainstorm Cell Therapeutics (BCLI), Asure Software (ASUR) and Acer Therapeutics (ACER). Who are Gerresheimer's key executives? Gerresheimer's management team includes the folowing people: Mr. Dietmar Siemssen, CEO & Member of Management Board (Age 56)Dr. Lukas Burkhardt, Member of Management Board (Age 40)Ms. Katja Schnitzler, Group Director of Bus. Excellence & Continuous Improvement and Member of the Supervisory Board (Age 38)Ms. Severine Camp, Corp. Sr. Director of Investor RelationsMr. Jens Kürten, Group Sr. Director of Communication & Marketing and Press Officer of Corp. Media What is Gerresheimer's stock price today? One share of GXI stock can currently be purchased for approximately €66.05. How big of a company is Gerresheimer? Gerresheimer has a market capitalization of $2.07 billion and generates $1.39 billion in revenue each year. Gerresheimer employs 9,867 workers across the globe. What is Gerresheimer's official website? The official website for Gerresheimer is http://www.gerresheimer.com/. How can I contact Gerresheimer? Gerresheimer's mailing address is Klaus-Bungert-Strasse 4, DUESSELDORF, 40468, Germany. The company can be reached via phone at +49-211-618100. MarketBeat Community Rating for Gerresheimer (ETR GXI)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 174 (Vote Outperform)Underperform Votes: 187 (Vote Underperform)Total Votes: 361MarketBeat's community ratings are surveys of what our community members think about Gerresheimer and other stocks. Vote "Outperform" if you believe GXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GXI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: Why do commodities matter? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.